Can GSM cause burning, itching or micro-tears?
Can GSM cause burning, itching or micro-tears? Yes—genitourinary syndrome of menopause (GSM) can lead to thinning, dryness and higher pH, which make the vulvo-vaginal tissue more fragile. This may feel like burning or itching and can result in micro-tears, especially with friction from sex, tampons or sport. A step-wise plan with moisturisers, suitable lubricants and, if needed, local oestrogen or DHEA often helps. See a clinician to rule out infections or skin conditions. Educational only. Results vary. Not a cure.
Detailed Medical Explanation
Can GSM cause burning, itching or micro-tears? Yes. In peri- and post-menopause, lower oestrogen changes the vaginal epithelium and vulval skin. The lining becomes thinner and less elastic (often labelled “vaginal atrophy”), blood flow and natural lubrication fall, and the vaginal pH rises as protective lactobacilli decline. Together these shifts—central to genitourinary syndrome of menopause (GSM)—make tissues more prone to irritation and small fissures. That fragility explains symptoms such as burning, itching, rawness after sex, stinging with urine on the skin, and micro-tears that may cause light spotting.
How symptoms show up day to day. People often notice soreness with penetrative sex (dyspareunia), a sandpaper-like sensation during long walks or cycling, or a scratchy feeling inserting a tampon or menstrual cup. Itching may be mild and intermittent, or more persistent after perfumed washes, bubble baths or tight sportswear. Burning can follow friction or appear with higher vaginal pH. Urinary urgency or frequency may accompany these symptoms because the urethra and bladder trigone are also oestrogen-responsive.
Why micro-tears happen. When lubrication is reduced and the epithelium is thin, shear forces increase during intercourse or even routine activity. Small fissures—especially at the posterior fourchette—are common. They tend to heal but can recur if dryness and friction persist. Adequate baseline hydration of the tissue (regular vaginal moisturiser) plus event-based lubrication before sex or examinations reduces this cycle.
Not everything that burns or itches is GSM. Symptoms can overlap with contact dermatitis (fragranced soaps, wipes, pantyliners), lichen sclerosus (white patches, fissures), vestibulodynia (provoked pain at the entrance), or infections such as thrush or bacterial vaginosis. New malodorous discharge, cottage-cheese-like discharge, ulcers, fever, pelvic pain, or post-menopausal bleeding warrant assessment. A clinician can distinguish these and tailor care.
What you can do now. Adopt gentle vulval care: rinse with lukewarm water, use a bland emollient as a soap substitute externally, and avoid perfumes. Schedule a vaginal moisturiser several times weekly to rehydrate the epithelium over time (some include hyaluronic acid). For intimacy, choose a personal lubricant matched to your needs: water-based (versatile, condom-friendly), silicone-based (long-lasting glide for significant dyspareunia), or oil-based (rich feel but may degrade latex condoms and some sex toys). Allow unhurried arousal, consider positions that reduce stretch at the entrance, and pause if stinging develops.
When to consider medical treatments. If symptoms persist despite consistent self-care, local vaginal oestrogen (cream, pessary/tablet, or ring) or vaginal DHEA may restore the tissue environment, improving lubrication, elasticity and pH. Systemic HRT can help whole-body menopausal symptoms but often needs to be paired with local therapy for GSM. Pelvic floor physiotherapy can ease muscle over-guarding triggered by pain, and psychosexual therapy can rebuild confidence and comfort when fear-avoidance patterns have developed.
Planning next steps. A structured pathway helps you move from basics to targeted options. For an overview of how care is delivered, see our page on common clinical concerns we assess and how treatment steps are sequenced. Device-based approaches (e.g., laser or radiofrequency) and regenerative injectables (e.g., platelet-rich plasma or polynucleotides) are not first-line; decisions about these should weigh benefits, uncertainties, costs and regulatory status against your goals.
Where to read more. Trusted sources cover symptoms, self-care and guideline-based treatments. Start with the NHS overview of vaginal dryness. Management principles are set out in the NICE Menopause Guideline (NG23). For evidence syntheses on local oestrogen, see the Cochrane Library, and for clinical reviews on terminology and options (GSM, dyspareunia, DHEA, moisturisers) see peer-reviewed articles indexed on PubMed. Dermatology guidance on lichen sclerosus helps differentiate mimics and manage skin fragility.
Clinical Context
Who is more likely to experience burning, itching or micro-tears with GSM? Anyone in late perimenopause or post-menopause, especially after early menopause, oophorectomy, or if systemic HRT is unsuitable or declined. Sensitive skin, prior dermatitis, frequent use of fragranced products, or high-friction activities (long-distance cycling, running) can amplify symptoms. Dyspareunia often co-exists with superficial fissures at the entrance, and urinary urgency/frequency may appear even when dryness seems mild.
Who should be cautious or seek review first? If you have active genital infection, unhealed tears, recent pelvic surgery, unexplained bleeding, visible ulcers, or new patterned white plaques suggestive of lichen sclerosus, arrange assessment before starting new products or procedures. If there is a history of hormone-sensitive cancer, discuss local oestrogen or DHEA with oncology and menopause teams to balance benefits and risks. Alternatives and adjuncts include scheduled non-hormonal moisturisers/lubricants, pelvic floor physiotherapy, and psychosexual therapy. Plan review after 6–12 weeks to adjust the regimen to the lowest effective schedule.
Evidence-Based Approaches
Guidelines recommend a step-wise pathway. The NICE Menopause Guideline (NG23) advises offering information on vaginal moisturisers and lubricants and considering low-dose local vaginal oestrogen for GSM when symptoms affect quality of life. Choice of product (estradiol/estriol cream, pessary/tablet, or estradiol ring) should reflect preference, dexterity and symptom pattern; many continue maintenance doses long term to sustain benefits. NHS advice on vaginal dryness covers practical self-care and when to seek help.
Cochrane syntheses show that low-dose vaginal oestrogens improve dryness, soreness, dyspareunia and pH compared with placebo, with broadly similar efficacy across formulations and low systemic absorption at licensed doses. See the Cochrane Library for pooled estimates and safety data. Peer-reviewed reviews indexed on PubMed summarise GSM terminology, mechanisms (thinning epithelium, higher pH), and options including vaginal DHEA.
For mimics of GSM-related symptoms, dermatology guidance from the British Association of Dermatologists outlines diagnosis and care for lichen sclerosus, a cause of fissures and itching that needs specific treatment. Non-hormonal moisturisers (including hyaluronic-acid-based products) can support hydration for those avoiding hormones, though effects may be smaller and require consistent use. Energy-based devices (laser/radiofrequency) and regenerative injectables (PRP/polynucleotides) remain areas of evolving evidence and are not first-line in guidelines.